Effect of statin therapy on pulse wave velocity: A meta-analysis of randomized controlled trials by D’Elia, Lanfranco et al.
Full Terms & Conditions of access and use can be found at
http://www.tandfonline.com/action/journalInformation?journalCode=iceh20
Clinical and Experimental Hypertension
ISSN: 1064-1963 (Print) 1525-6006 (Online) Journal homepage: http://www.tandfonline.com/loi/iceh20
Effect of statin therapy on pulse wave velocity: A
meta-analysis of randomized controlled trials
Lanfranco D’elia, Ersilia La Fata, Arcangelo Iannuzzi & Paolo O. Rubba
To cite this article: Lanfranco D’elia, Ersilia La Fata, Arcangelo Iannuzzi & Paolo O. Rubba (2018):
Effect of statin therapy on pulse wave velocity: A meta-analysis of randomized controlled trials,
Clinical and Experimental Hypertension, DOI: 10.1080/10641963.2017.1411498
To link to this article:  https://doi.org/10.1080/10641963.2017.1411498
Published online: 08 Feb 2018.
Submit your article to this journal 
Article views: 42
View related articles 
View Crossmark data
Effect of statin therapy on pulse wave velocity: A meta-analysis of randomized
controlled trials
Lanfranco D’elia a, Ersilia La Fataa, Arcangelo Iannuzzib, and Paolo O. Rubbaa
aDepartment of Clinical Medicine and Surgery, “Federico II” University of Naples Medical School, Naples, Italy; bDepartment of Medicine and
Medical Specialties, A. Cardarelli Hospital, Naples, Italy
ABSTRACT
Background and Objective: Arterial stiffness (AS) is an independent cardiovascular risk factor. A number of
studies have reported a beneficial role of statins on AS albeit with controversial results, in addition to their
effects on lipid profile. Therefore, we carried out ameta-analysis of the available randomized controlled trials
assessing the effects of statin therapy on AS, in the attempt to reach more definitive conclusions.Methods: A
systematic search of the on-line databases available up to March 2017 was conducted, including interven-
tion studies reporting AS expressed by carotid-femoral pulse wave velocity (PWV), as difference between the
effects of treatment with or without statins. For each study, mean difference (MD) and 95% confidence
intervals (CI) were pooled using a random effect model. Results: Eleven studies met the pre-defined inclusion
criteria, for a total of 573 participants and 2–144 weeks’ intervention time. In the pooled analysis, statin
therapy was associated with a −6.8% (95% C.I.: −11.7 to −1.8) reduction in PWV. There was significant
heterogeneity among studies (I2 = 96%); none of the study characteristics seems to have influenced the
effect of statin use on PWV. Conclusions: The results of this meta-analysis suggest that statin therapy reduces
AS. This effect appears to be at least in part independent of the changes in blood pressure and lipid profile.
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Introduction
Carotid-femoral pulse wave velocity (PWV), the gold stan-
dard of non-invasive arterial stiffness measurement, is an
independent predictor of cardiovascular outcomes in both
the general population and patients at high risk of cardio-
vascular disease (1 –3). A number of studies have reported
a beneficial role of statins on arterial stiffness, in addition
to their effects on lipid profile (4). In particular, experi-
mental studies have shown a favorable pleiotropic effect of
statins on cardiovascular risk through their role in enhan-
cing nitric oxide bioavailability (5), their antioxidant effect
(6), and their interaction with the renin-angiotensin-aldos-
terone system (7).
However, some of the intervention studies carried out were
flawed by their low statistical power and the heterogeneity of
the participants’ features (4,8–10). Recently, a meta-analysis
also tried to provide definite evidence of the favorable effect of
statin therapy on arterial stiffness (11), but this study as well
had major limitations, as it included studies using different
indices of arterial stiffness, did not report other published
randomized controlled trials, and did not assess possible con-
founders of the relationship.
In the attempt to provide stronger evidence of the role of
statins on arterial stiffness, we carried out a meta-analysis of
the available randomized clinical trials meeting strictly pre-
defined inclusion criteria to test the hypothesis that statin use
reduces PWV—as estimate of arterial stiffness, calculate the
extent of this effect and, lastly, evaluate the effect of potential
confounders on this relationship.
Methods
Data sources and search strategy
This meta-analysis was planned, conducted, and reported
according to the PRISMA statement (12) (Supplementary
Table S1). We performed a systematic search of the available
publications using MEDLINE, Scopus, and the Cochrane
Library, up to March 2017 (updated to 29 March 2017). The
search strategy,without restrictions, used the expressions “statin”
OR “statins” OR “HMG-coa reductase inhibitor” AND “pulse
wave velocity” OR “PWV” OR “arterial stiffness” OR “aortic
stiffness” OR “arterial compliance”, or combinations thereof,
either in medical subject headings or in the title/abstract.
Further information was retrieved through a manual search of
references from recent reviews and relevant published original
studies.
Study selection
For a published study to be included in the meta-analysis, the
following criteria had to be met: (a) original article, (b) adult
population study, (c) randomized controlled trial, (d)
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indication of a difference in PWV between statin use and no
statin use in one or more patients’ cohorts, (e) indication of
the number of participants included in the exposed and con-
trol group of each cohort.
Data extraction and quality assessment
Two reviewers (LD, ELF) independently assessed study eligibility
and extracted the data. Discrepancies over the inclusion of studies
and the interpretation of the data were resolved in conference, and
consensus was reached after discussion.
The main characteristics of the studies identified and the
respective populations are recorded and reported in Table 1. The
risk of bias of the studies included in the meta-analysis was
independently assessed by two reviewers (LD, ELF) according to
established criteria (16), and reported in Supplementary Table S2.
Statistical analysis
A detailed description of the statistical methods has been reported
previously (17,18). Mean differences (MD) and standard error
(SE) of the defined outcomes were extracted from the selected
publications. In case these were not available, MD and SE were
calculated from the comparison of the outcomes during statin
therapy against no statin use. Because of the heterogeneity
among studies of baseline levels and the subsequent changes, the
between-regimen changes in PWV were utilized in the analyses
after conversion to percentages. The pooled MD and 95%
confidence interval (CI) was estimated using a random-effect
model (19). The Cochrane Q test and the I2 statistic were used to
evaluate statistical heterogeneity across the studies. Funnel plots
were constructed and visually assessed for possible publication
bias (20). Egger’s weighted regression test and Begg’s rank correla-
tion test were also used to explore potential publication bias. In
case of significant funnel plot asymmetry, the pooledMD estimate
was recalculated by the “trim and fill”method (21). The influence
of the individual cohorts or of a particular study was estimated by
sensitivity analysis. Moreover, meta-regression and subgroup ana-
lyses were used to identify associations between changes in PWV
and relevant study or patient characteristics as possible sources of
heterogeneity. Given the substantial difference in treatment dura-
tion between the study carried out by Fassett et al (13) and other
trials included, separate analyses were also performed excluding
this study. All statistical analyses were performed using the Stata
Corp. software (version 11.2, College Station, Texas, USA) and the
graphic representation was carried out by MIX software (version
1.7, Kitasato Clinical Research Center, Kanagawa, Japan) (22).
Results
Characteristics of the studies included in the meta-
analysis
Of a total of 662 publications retrieved (Figure 1), 24 studies
were potentially relevant and were reviewed in full-text (8–
10,13–15,23–41). Thirteen of them were excluded because
Table 1. Characteristics of the studies included in the meta-analysis.
First Author,
year (ref) Country
Cohort
(n. of participants)
Selected features of the study
participants
Mean
Age
(yrs)
Mean BMI
(Kg/m2)
Duration of
intervention
(wks)
Assessment
Method
Comparison
(n. of
participants)
Study
Design
Fassett et al.
(13)
Australia CKD patients
(21M,13W)
CKD (serum creatinine >1.36 mg/
dL), all levels of serum cholesterol
and proteinuria
63.6 28.6 144 Applanation
tonometry
(Sphygmocor)
Atorvastatin
10 mg (16)
vs Placebo
(18)
PA-DB
Wallaceet al.
(8)
United
Kingdom
Healthy participants
(24M,26W)
Volunteers without cardiovascular
risk factors
26.0 23.2 2 Applanation
tonometry
(Sphygmocor)
Simvastatin
40 mg (25)
vs Placebo
(25)
PA-DB
Kanaki et al.
(14)
Greece Hypertensive and
Hypercholesterolemic
patients (24M,26W)
Hypertension (SBP: 140–160, DBP:
90–100 mm Hg, under
antihypertensive treatment - 1
agent or stage 1 hypertension
without treatment),
Hypercholesterolemia without
hypolipidemic treatment (LDL
>3.4 mmol/L associated with 1–2
cardiovascular risk factors or LDL
> 3.9 mmol/L at low
cardiovascular risk)
59.2 29.5. 26 Applanation
tonometry
(Sphygmocor)
Atorvastatin
10 mg (25)
vs Placebo
(25)
PA-DB
Joyeux-Faure
et al. (9)
France,
Switzerland
OSA patients (40M,
11W)
OSA, no CVD, no statin and
antihypertensive treatment
54.0 28.5 12 Pressure
transducer
(Complior)
Atorvastatin
40 mg (25)
vs Placebo
(26)
PA-DB
Ballard et al.
(15)
US Patients with statin
myalgia (67M, 48W)
Myalgia during statin treatment 60.3 28.4 8a Applanation
tonometry
(Sphygmocor)
Simvastatin
20 mg (100)
vs Placebo
(100)b
CO-DB
John et al.
(10)
United
Kingdom
COPD patients (50M,
20W)
COPD, hypercholesterolemia
<6.5 mmol/L
64.5 - 6 Applanation
tonometry
(Sphygmocor)
Simvastatin
20 mg (31)
vs Placebo
(32)b
PA-DB
M: men; W: women; CAD: coronary artery disease; CO: crossover; PA: parallel-arm; DB: double-blind; OL: open-label intervention; CVD: cardiovascular disease; SBP:
Systolic blood pressure; DBP: Diastolic blood pressure; OSA: obstructive sleep apnea; CKD: chronic kidney disease; COPD: chronic obstructive pulmonary disease; a
the duration of intervention in myalgic patients was comprised between 1 and 3 weeks b PWV available for a sub-group of participants.
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they reported the outcomes as difference from baseline (28–
32) or did not report outcomes of interest (33–40). Overall, 11
studies met the inclusion criteria and were used for the meta-
analysis (8–10,13–15,23–27). The relevant features of the stu-
dies are provided in Table 1. The meta-analysis involved a
total of 573 male and female participants from 10 countries
six from Europe, 2 from the USA and Australia, and 1 from
China. The duration of the interventions ranged from 2 to
144 weeks.
Nine studies recruited patients with hypercholesterolemia
—this was the only disease in two studies (23,25)—while in
the other studies hypercholesterolemia was associated with
hypertension (14,24), mialgia (15), coronary artery disease
(26), owerweight/obesity (27), obstructive sleep apnea syn-
drome (9), or chronic renal failure (13); lastly, only one
study included healthy participants (8) or patients with
chronic obstructive pulmonary disease (10). All the studies
recruited both male and female participants. PWV was
assessed by different methods, six studies using applanation
tonometry (Sphygmocor device - PWV Medical Pty. Ltd.,
Sidney, Australia) (8,10,13–15,25) and the other investigations
using a pressure transducer (three the Complior device,
Colson Medicals, France; one Windaq, and other one generic
brand) (9,23,24,26,27). All had a cross-over design (15,23),
except for two which had a parallel-arms design. Nine inves-
tigations were double blinded for the use of placebo, whereas
another one was open-label (25). Blinding was not specified in
one study (26). Six studies evaluated the effects of
Atorvastatin, four estimated the effects of Simvastatin, and
only one assessed the effects of Rosuvastatin (25). External
funding sources were declared in all but two studies (25,26);
five received pharmaceutical industry funding. The evaluation
of the “risk of bias” indicated that all studies were at low-risk
(Supplementary Table S2).
Effect of statin use on PWV
Detailed features of the eleven studies (with overall 573 parti-
cipants) included in this analysis are given in Table 1 and
Supplementary Table S2 (8–10,13–15,23–27). In the pooled
analysis, the use of statins was associated with a significantly
lower average PWV (–6.8%, 95% CI: −11.7 to −1.8; p < 0.01)
compared with no use. There was significant between-study
heterogeneity (Q = 245.5, p < 0.01; I2 = 96%) (Figure 2).
The evaluation of the individual studies showed a trend
toward a favorable association between statin use and PWV in
eight studies (10,13–15,23,25–27), with a significant reduction
in five of them (14,15,25–27). Conversely, a non-significant
adverse association was observed in another three investiga-
tions (8,9,24). Sensitivity analysis showed that the average
change in PWV did not vary substantially when any indivi-
dual study was excluded (Supplementary Table S3). The fun-
nel plot for the effect of statin use on PWV change indicated
an asymmetrical distribution at the visual inspection.
Although Egger’s and Begg’s tests did not detect a significant
publication bias (Egger: p = 0.72, Begg: p = 0.62), the “trim
and fill” method, which identified three possibly missing
studies, showed a change of the effect from −6.8% to
−10.5% in PWV (MD = −10.5%; −15.7% to −5.4%).
Pooled analysis excluding the study by Fassett and collabora-
tors (13) (including ten studies and 539 total participants)
showed that statin use was associated with a significant and
favorable effect on PWV (MD = −7.2%, 95% CI: −12.4 to −1.9;
p < 0.01) compared with no use. The sensitivity analysis did not
Figure 1. Stepwise procedure for selection of the studies.
Flowchart indicating the results of the systematic review with inclusions and exclusions.
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show substantially changes in the effect of statin use
(Supplementary Table S4). There was a significant heterogeneity
among studies (Q = 244.0, p < 0.01; I2 = 96%), and there was no
evidence of publication bias (Egger’s test: p = 0.67, Begg’s test:
p = 0.59). However, the “trim and fill” method once again
identified two possibly missing studies, modifying the pooled
estimate to a MD of −9.9% (95% CI: −15.0% to −4.9%).
Additional analyses
The meta-regression analysis indicates that the lipid profile,
that is, total cholesterol, LDL-cholesterol, triglycerides and
HDL-cholesterol, did not affect the effect of statin on PWV,
either at baseline or after treatment (p > 0.05) (Table 2,
Supplementary Table S5). Likewise, baseline blood pressure
(BP) values and their changes after treatment (i.e. systolic and
diastolic BP, and mean arterial pressure) did not affect the
relationship between statin use and PWV changes (p > 0.05)
(Table 2, Supplementary Table S5).
A separate analysis including the studies with hypercholes-
terolemic participants (9,13–15,23–27) found a favorable
effect of statin use on PWV (MD = −7.7%, −13.3 to −2.1;
p < 0.01), also when the study by Fassett and collaborators
was excluded (MD = −8.3%, −14.3 to −2.3; p < 0.01). The
analysis stratified by countries of study development sug-
gested a stronger association between statin use and changes
in PWV in studies performed in the USA compared to those
carried out in Europe, Australia and China, but the compar-
ison did not achieve statistically significant difference
(Table 3, Supplementary Table S6).
Likewise, the studies that utilized applanation tonometry as
instrumental method for measurement of PWV tended to
provide a stronger effect of statin use than those utilizing
pressure transducer, but the comparison did not achieve sta-
tistically significant difference (Table 3, Supplementary
Table S6). In addition, subgroup analysis in relation to the
type of statin utilized did not detect significant differences in
the effect produced (Table 3, Supplementary Table S6).
Age, BMI, year of publication, total number of participants,
gender, and length of the intervention and PWV at baseline
were no significant sources of heterogeneity by meta-regres-
sion analyses (Table 2, Supplementary Tables S5).
Discussion
The results of this meta-analysis indicate a direct association
between statin use and decreased arterial stiffness in the con-
trolled randomized intervention trial of statin use having
PWV changes as the main endpoint. This effect appears to
be at least in part independent of the changes in BP and lipid
profile.
This finding was strengthened by the detection of a favor-
able effect in as many as 8 of the 11 individual cohorts
included in the analysis and by the observation that a (not
significant) opposite trend was reported in only three studies
(8,9,24). However, one of them included a sample of healthy
young participants with low PWV at baseline, and short
length of intervention (8). Another study involved patients
with obstructive sleep apnea syndrome, without comorbid-
ities, and that exhibited low stiffening at baseline (9). Finally,
the unfavorable effect was found in a small study with parti-
cipants on stable antihypertensive therapy, in whom the vas-
cular benefit of statin use may have been concealed (24).
Although PWV is known to be strongly associated with age
(41,42), we failed to find significant differences in the effect of
statin use on PWV as a function of the mean age of the
various study cohorts. It is worth noting that a reduction in
BP was observed in eight of the 11 studies; two did not report
any information on BP (15,26), while only one detected an
increase in BP after treatment (24). The greater reduction in
BP was observed in participants without antihypertensive
treatment (9), while the inverse effect of statin on BP was
described in a small trial with patients on stable antihyperten-
sive therapy (24). Despite the strong association between BP
and PWV (41,42), and also the evidence of a favorable effect
Figure 2. Effect of statin use on carotid-femoral pulse wave velocity (PWV).
Forest plot of the effect of statin use on PWV in 11 published studies. Results are expressed as Mean Difference (MD) (%) and 95% confidence intervals (95% CI).
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of statin use on BP (43), the results of our meta-regression
analysis suggest that the effect of statin use on PWV changes
may be independent of the BP changes that occurred during
the trials. Likewise, also baseline BP values of the individual
studies were not a significant source of heterogeneity.
In all the studies included, there was a significant reduction
in total cholesterol during statin therapy, ranging from
0.8 mmol/L in healthy participants (8) to 2.3 mmol/L in
patients with sleep apnoea (9). In addition, three of these
studies found a positive association between changes in total
and LDL cholesterol, and PWV changes (15,25,27). Despite
the favorable effect of statin use on cholesterol levels, the
changes observed did not affect the relationship between
statin use and the reduction in PWV by meta-regression
analysis. Similar results were also found for all other lipid
parameters evaluated.
Subgroup analysis by type of statin only explored the
comparison between atorvastatin and simvastatin—the two
most representative classes. Despite the data showing different
power between statin classes in terms of cholesterol reduction
(44), the comparison did not detect significant difference in
the effect of statin treatment on PWV. Analysis stratified by
different geographical location suggested a better (but not
statistically different) effect in the US than in Europe,
Australia or China. However, this result may be affected by
the small number of studies included in the subgroup.
Similarly to what reported by Salvi and collaborators (45),
our analysis shows a trend towards differing results in relation
to the instrumental method used for PWV measurement,
although the difference was not confirmed by subgroup ana-
lysis. Noteworthy, there was a large difference between dura-
tion of the trials included, from 2 to 144 weeks, but the meta-
regression analysis did not show this difference as source of
heterogeneity. Other meta-regression analyses failed to find
any significant influence for number of participants, gender,
BMI and PWV at baseline.
According to the meta-analysis by Upala et al., statin use
was associated with reduced arterial stiffness (11). That study
was also characterized by severe limitations: the number of
randomized controlled trials included was smaller, the indices
of arterial stiffness adopted in the studies were different (four
studies evaluated carotid-femoral PWV (8,14,25,27), one bra-
chial-ankle PWV (40) and other one carotid PWV (39)), and
no potential confounders were explored. Conversely, our
meta-analysis included a larger number of randomized con-
trolled trials reporting only the values of carotid-femoral
PWV, and took into account a large number of potential
confounders.
Our study had no specific potential to address the mechanisms
of the effect of statin use on arterial stiffness. It is possible that
statins exert direct effects on the arterial wall and its components,
above and beyond those produced by the changes in lipid para-
meters (pleiotropic effect). Statin treatment may reduce vascular
tone by enhancing the nitric oxide availability through the
increased expression of endothelial nitric oxide synthase (5,46).
Statin therapy may also decrease oxidative stress, by inhibiting
reactive oxygen species production (6). Several experimental stu-
dies point to the renin-angiotensin-aldosterone system as possible
target. Indeed, statin treatment has been shown to down-regulate
the expression of angiotensin II type 1 (AT1) receptor in the
vascular smooth muscle cells (7,47), and to counteract the effect
of concomitant structural alteration in arterial wall mediated by
angiotensin II (48). In addition, statins may inhibit endothelin-1
production in vascular smooth muscle cells (49,50), thus reducing
the sympathetic activity (51).
In addition to the pleiotropic effect, the heterogeneity among
participants included could at least in part explain the (BP and
lipid profile) independent effect of statins on PWV. Indeed, the
trials included were carried out on cohorts both at high cardiovas-
cular risk (e.g. patients with coronary artery disease or chronic
kidney disease) and at low risk (e.g. healthy participants). Also the
different on-going therapy and duration of the treatment (e.g. use
of antihypertensive therapy), as well as the different age or weight
among participants, could affect the relationship. In addition, the
lifestyle of the participants, such as physical activity or dietary
Table 2. Meta-regression analysis of the effect of statin treatment on pulse wave
velocity.
Variables (n. of studies)
ΔPWV (%)
(coefficient) 95% CI
p-
value
Age (years) (11) −0.29 −0.98 to 0.31 0.30
BMI (Kg/m2) (10) −0.70 −3.99 to 2.57 0.63
Year of publication (year) (11) −0.53 −2.11 to 1.04 0.46
Length of intervention (week) (11) 0.01 −0.17 to 0.18 0.93
Number of participants (n) (11) −0.08 −0.33 to 0.17 0.51
Gender (% men) (11) 0.52 −0.01 to 1.05 0.05
PWV at baseline—statin group (10) −1.72 −5.03 to 1.58 0.26
PWV at baseline—not statin group
(10)
−1.61 −4.91 to 1.68 0.29
Total Cholesterol at baseline (mmol/L)
(11)
0.03 −8.31 to 8.38 0.99
LDL-cholesterol at baseline (mmol/L) (11) −2.23 −11.39 to 6.92 0.59
Triglycerides at baseline (mmol/L) (9) −0.15 −7.47 to 7.17 0.96
HDL-cholesterol at baseline (mmol/L)
(11)
23.62 −2.65 to 49.89 0.07
Total cholesterol difference (mmol/L) (11) −1.47 −16.92 to 13.98 0.83
LDL-cholesterol difference (mmol/L) (10) 1.40 −6.14 to 8.94 0.68
Triglycerides difference (mmol/L) (8) 5.77 −10.63 to 22.17 0.42
HDL-cholesterol difference (mmol/L) (10) 14.00 −17.94 to 45.95 0.34
Systolic blood pressure at baseline (mm
Hg) (11)
−0.09 −0.69 to 0.50 0.73
Diastolic blood pressure at baseline (mm
Hg) (11)
0.04 −1.23 to 1.30 0.95
Mean arterial pressure at baseline (mm
Hg) (11)
−0.07 −1.06 to 0.92 0.88
Systolic blood pressure difference (mm
Hg) (8)
0.62 −2.47 to 3.71 0.64
Diastolic blood pressure difference (mm
Hg) (8)
1.58 −2.94 to 6.10 0.42
Mean arterial pressure difference (mm
Hg) (8)
0.94 −3.58 to 5.47 0.63
PWV: pulse wave velocity, CI: confidence interval.
Table 3. Subgroup analysis of the effect of statin treatment on pulse wave
velocity.
Variables (n. of
cohorts)
Pooled
mean (%)
reduction
PWV 95% CI
p for
heterogeneity
Country of
origin
Europe (6) −5.2 −14.8 to 4.4 0.9
US (2) −7.1 −12.6 to −1.6
AUS - China (3) −7.6 −18.2 to 2.9
PWV
assessment
device
Pressure
transducer (5)
−3.6 −13.2 to 5.9 0.4
Applanation
tonometry (6)
−8.5 −15.0 to −1.9
Type of statin Atorvastatin (6) −7.2 −15.4 to 1.0 0.4
Simvastatin (4) −2.8 −7.7 to 2.1
PWV: pulse wave velocity, CI: confidence interval
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habits—not evaluated at baseline and during intervention—may
potentially affect the results. However, the process of meta-analy-
sis, with the calculation of a pooled estimate of the effect, is
functional to overcome at least in part this problem.
The following are the major strengths of our meta-analysis:
i) the inclusion of randomized controlled trials only; ii) the
inclusion only of studies reporting carotid-femoral PWV—the
gold standard of non-invasive measurement of arterial stiff-
ness; iii) all the studies provided cohorts at “low” risk of bias;
iv) the finding of a trend to reduction of arterial stiffness
during statin use in most cohorts; v) the evaluation of a
large number of possible sources of heterogeneity.
On the other hand, the value of our findings is limited by
the relatively small number of study cohorts available, by the
small number of participants enrolled in the individual trials,
and by the large number of features of the participants
included. Nevertheless, the effect of statins was significantly
favorable in a separate analysis including only the studies with
hypercholesterolemic participants.
Furthermore, given the large difference in the duration of the
observation between Fassett’s investigation and the other studies,
the analyses were conducted also without the former (13), yielding
similar results. Another limitation is the detectable publication
bias, although the “trim and fill” method identified a number of
possibly missing studies and indicated an underestimation of the
effect of statin. Given the heterogeneity of the type of statin utilized
and the limited data for individual class, we were unable to
examine a possible dose-response relationship. Finally, a weakness
of our study is the fact that no definitive conclusions can be drawn
on the long-term effects of statin use on arterial stiffness, since only
three of the trials included in themeta-analysis had an intervention
period longer than 12 weeks.
In conclusion, the results of this meta-analysis show that use of
statin reduces arterial stiffness, at least in part independently of
concomitant changes in BP and lipid levels. Given the importance
of arterial stiffness as predictor of cardiovascular and all-cause
mortality (1–3,52), the effect of statin significantly adds to its
already recognized value in cardiovascular disease prevention.
Indeed, based on previous studies indicating increments in cardi-
ovascular events andmortality for each 1m/s increase in PWV (3),
a 7%decrease in PWVwith statin use is expected to translate into a
substantial reduction in cardiovascular risk. In consideration of
our results, statin use may be beneficial for hypercholesterolemic
patients but also for patients affected by other conditions (28,32).
On research grounds, our systematic review underlines the lack
of properly powered randomized controlled trial of the effect of
long-term statin use on arterial stiffness; therefore, an effort in this
direction is warranted to further support the conclusions of our
meta-analysis and expand current knowledge in this field.
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